Uridine Triacetate Antidote Therapy Therapeutics
1. Xuriden patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6258795 | BTG INTL | Acylated uridine and cytidine and uses thereof |
Jul, 2023
(2 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2020 |
| Orphan Drug Exclusivity(ODE) | Sep 04, 2022 |
| Orphan Drug Exclusivity(ODE-98) | Sep 04, 2022 |
Drugs and Companies using URIDINE TRIACETATE ingredient
NCE-1 date: 05 September, 2019
Market Authorisation Date: 04 September, 2015
Dosage: GRANULE
More Information on Dosage
XURIDEN family patents
